Serum-circulating His-tRNA synthetase inhibits organ-targeted immune responses
Ryan A. Adams(aTyr Pharma (United States)), Paul Schimmel(Scripps Research Institute), Antonella Notarnicola(Karolinska University Hospital), Cátia Fernandes‐Cerqueira(Karolinska University Hospital), John Mendlein(aTyr Pharma (United States)), Sanna Rosengren(University of California San Diego), Elisabeth Mertsching(aTyr Pharma (United States)), Kathleen M. Ogilvie(aTyr Pharma (United States)), Andrea Cubitt(aTyr Pharma (United States)), Zhiwen Xu(Guangxi Medical University), Leslie A. Nangle(aTyr Pharma (United States)), David J. King(Regulus Therapeutics (United States)), Jeanette Ampudia(aTyr Pharma (United States)), Wing‐Sze Lo(Hong Kong University of Science and Technology), Kyle P. Chiang(aTyr Pharma (United States)), Xiang‐Lei Yang(Scripps Research Institute), Per‐Johan Jakobsson(Karolinska University Hospital), Ingrid E. Lundberg
Cited by 39
Related Papers
Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin
|Journal of Clinical Investigation|2012|708
High-Level Expression of a Recombinant Antibody from Myeloma Cells Using a Glutamine Synthetase Gene as an Amplifiable Selectable Marker
|Nature Biotechnology|1992|465
A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody
|Molecular Immunology|1993|243
Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells.
|PubMed|1996|212
Fibrin-targeting immunotherapy protects against neuroinflammation and neurodegeneration
|Nature Immunology|2018|210